Positron Corporation Announces Sale of NeuSight PET-CT Scanner
Positron (OTC: POSC) has announced the sale of its NeuSight PET-CT 64 slice scanner to a leading cardiovascular services provider. The NeuSight PET-CT is designed to revolutionize cardiac PET imaging, offering advanced technology at a competitive price. Key features include:
- 500 installations worldwide
- 72cm gantry for patient comfort
- High-sensitivity acquisition technology for minimal radiation exposure
- Smallest footprint and lightest weight in its class
- Suitable for cardiology and oncology studies
- Superior data acquisition and improved scanning speed and accuracy
Positron's President, Adel Abdullah, expressed enthusiasm about the sale and the positive market response since the scanner's introduction in late July. The company aims to continue offering this technology to practices and hospitals in the future.
Positron (OTC: POSC) ha annunciato la vendita del suo scanner NeuSight PET-CT a 64 strati a un importante fornitore di servizi cardiovascolari. Il NeuSight PET-CT è progettato per rivoluzionare l'imaging cardiaco PET, offrendo tecnologia avanzata a un prezzo competitivo. Le caratteristiche principali includono:
- 500 installazioni in tutto il mondo
- Gantry da 72 cm per il comfort del paziente
- Tecnologia di acquisizione ad alta sensibilità per un'esposizione minima alle radiazioni
- Ingombro più ridotto e peso più leggero nella sua classe
- Adatto per studi di cardiologia e oncologia
- Acquisizione dati superiore e miglioramento della velocità e precisione della scansione
Il presidente di Positron, Adel Abdullah, ha espresso entusiasmo per la vendita e la positiva risposta del mercato dalla presentazione dello scanner a fine luglio. L'azienda intende continuare a offrire questa tecnologia a studi e ospedali in futuro.
Positron (OTC: POSC) ha anunciado la venta de su escáner NeuSight PET-CT de 64 cortes a un importante proveedor de servicios cardiovasculares. El NeuSight PET-CT está diseñado para revolucionar la imagenología cardíaca PET, ofreciendo tecnología avanzada a un precio competitivo. Las características clave incluyen:
- 500 instalaciones en todo el mundo
- Gantry de 72 cm para la comodidad del paciente
- Tecnología de adquisición de alta sensibilidad para una mínima exposición a la radiación
- La huella más pequeña y el peso más ligero en su clase
- Adecuado para estudios de cardiología y oncología
- Adquisición de datos superior y mejora de la velocidad y precisión del escaneo
El presidente de Positron, Adel Abdullah, expresó entusiasmo por la venta y la respuesta positiva del mercado desde la introducción del escáner a finales de julio. La compañía pretende seguir ofreciendo esta tecnología a consultorios y hospitales en el futuro.
포지트론 (OTC: POSC)은 주요 심혈관 서비스 제공업체에 NeuSight PET-CT 64 슬라이스 스캐너의 판매를 발표했습니다. NeuSight PET-CT는 심장 PET 이미징을 혁신하도록 설계되어 있으며, 경쟁력 있는 가격에 첨단 기술을 제공합니다. 주요 특징은 다음과 같습니다:
- 전세계 500개 설치
- 환자 편안함을 위한 72cm 갠트리
- 최소 방사선 노출을 위한 고감도 데이터 획득 기술
- 동급에서 가장 작은 면적과 가장 가벼운 무게
- 심장병학 및 종양학 연구에 적합
- 우수한 데이터 획득 및 향상된 스캔 속도와 정확성
포지트론의 사장인 아델 압둘라(Adel Abdullah)는 판매와 7월 말 스캐너 소개 이후 긍정적인 시장 반응에 대한 열정을 표명했습니다. 이 회사는 앞으로도 이 기술을 의원 및 병원에 제공하는 것을 목표로 하고 있습니다.
Positron (OTC: POSC) a annoncé la vente de son scanneur NeuSight PET-CT à 64 coupes à un fournisseur de services cardiovasculaires de premier plan. Le NeuSight PET-CT est conçu pour révolutionner l'imagerie cardiaque PET, offrant une technologie avancée à un prix compétitif. Les caractéristiques clés incluent :
- 500 installations dans le monde
- Gantry de 72 cm pour le confort du patient
- Technologie d'acquisition à haute sensibilité pour une exposition minimale aux radiations
- Empreinte la plus petite et poids le plus léger de sa catégorie
- Convient pour des études en cardiologie et oncologie
- Acquisition de données supérieure et amélioration de la vitesse et de la précision de la numérisation
Le président de Positron, Adel Abdullah, a exprimé son enthousiasme concernant la vente et la réponse positive du marché depuis l'introduction du scanneur fin juillet. L'entreprise prévoit de continuer à offrir cette technologie aux pratiques et hôpitaux à l'avenir.
Positron (OTC: POSC) hat den Verkauf seines NeuSight PET-CT 64-Schicht-Scanners an einen führenden Anbieter von kardiovaskulären Dienstleistungen bekannt gegeben. Der NeuSight PET-CT ist darauf ausgelegt, die kardiale PET-Bildgebung zu revolutionieren und bietet moderne Technologie zu einem wettbewerbsfähigen Preis. Wichtige Funktionen sind:
- 500 Installationen weltweit
- 72 cm großer Gantry für den Komfort des Patienten
- Hochsensitivität bei der Datenerfassung für minimalen Strahlungseinsatz
- Die kleinste Grundfläche und das leichteste Gewicht in seiner Klasse
- Geeignet für Studien in der Kardiologie und Onkologie
- Überlegene Datenerfassung und verbesserte Scan-Geschwindigkeit sowie Genauigkeit
Der Präsident von Positron, Adel Abdullah, äußerte Begeisterung über den Verkauf und die positive Marktreaktion seit der Einführung des Scanners Ende Juli. Das Unternehmen plant, diese Technologie auch in Zukunft Praxen und Krankenhäusern anzubieten.
- Sale of NeuSight PET-CT 64 slice scanner to a recognized leader in cardiovascular services
- NeuSight PET-CT has 500 installations worldwide, indicating market acceptance
- Competitive advantage with smallest footprint and lightest weight in the PET-CT 64 slice system industry
- Positive market response since the product's introduction in late July
- None.
Niagara Falls, NY, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to announce the sale of Positron’s NeuSight PET-CT 64 slice scanner to a recognized leader in preventive, invasive and interventional cardiovascular services.
The NeuSight PET-CT was designed to revolutionize cardiac PET imaging, offering unparalleled value, empowering practices with cutting-edge technology at an unmatched price. The NeuSight PET-CT scanner is a highly acclaimed, top performing scanner, with 500 installations throughout the world. An important feature is the systems design for patient comfort with a spacious 72cm gantry and high-sensitivity acquisition technology ensures safety with minimal radiation exposure for patients and technicians. The NeuSight PET-CT scanner has the smallest footprint and lightest weight of any PET-CT 64 slice system in the industry.
The NeuSight PET-CT scanner is an innovative, inexpensive PET-CT system making it ideal for both cardiology and oncology clinical studies having superior data acquisition, with identification technology for improved scanning speed and accuracy. The NeuSight PET-CT system provides anatomic and functional imaging with qualified designs and technology, serving multiple molecular imaging functions for heart, tumor, and brain imaging studies.
Adel Abdullah, President of Positron stated, “We are thrilled to have our first NeuSight PET-CT with such an esteemed cardiovascular physician and practice, dedicated to delivering expert cardiac care and we look forward to supporting their needs as they expand their practice in the future.”
Mr. Abdullah continued, “Since we introduced our NeuSight PET-CT in late July, we have been very pleased with the enthusiasm from many nuclear cardiologists who are interested in our PET-CT technology and its unmatched price point in the imaging market. The NeuSight PET-CT is the perfect solution for advanced nuclear cardiac studies, and we look forward to continuing to offer this unique combination of technology, services and value to practices and hospitals for many years to come.”
About Positron Corporation
Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.
Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.
Positron's Attrius® PET and NeuSight PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine.
Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.
Forward-Looking Statements
This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.
FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: investor@positron.com.
FAQ
What is the latest product sale announced by Positron (POSC)?
What are the key features of Positron's NeuSight PET-CT scanner?
How many installations of the NeuSight PET-CT scanner are there worldwide?
When did Positron (POSC) introduce the NeuSight PET-CT scanner?
